Abstract
To observe the long-term effects of an immune-based therapy HIV-1 Immunogen (REMUNE; Immune Response Corp., Carlsbad, CA, USA) as a first course of treatment designed to sustain the immune system and thus delay the initiation of therapy with antiretroviral drugs and/or delay disease progression. In this open-label, multi-institute extended phase II P2101B study, disease progression, CD4 and CD8 T-cell counts, HIV-1 RNA levels, and genotypic antiretroviral drug resistance were examined in 223 asymptomatic HIV-1-infected Thai volunteers receiving REMUNE every 12 weeks over 132 weeks. A subset of subjects was randomly selected by the physicians to receive antiretroviral drugs for 10 months. Patients treated with REMUNE demonstrated a low rate of clinical disease progression (0.72 per 100 person-years), higher CD4 and CD8 T-cell counts, higher body weight before and after treatment in the same patient, and stable viral load with no serious adverse events. We found no genotypic evidence of drug resistance in subgroups of patients on REMUNE monotherapy or REMUNE plus antiretrovirals (ARTs). This Thai study, like previous US and European studies, confirms that therapeutic immunization of HIV-infected volunteers modifies disease progre...Continue Reading
References
Apr 1, 1992·AIDS·S SirivichayakulW Thanyanon
Mar 1, 1990·Journal of Clinical Microbiology·R BoomJ van der Noordaa
Jan 1, 1995·Clinical Imaging·J FarmanH Rotterdam
Jan 27, 1993·JAMA : the Journal of the American Medical Association
May 1, 1996·Journal of Clinical Microbiology·H RevetsG Zissis
Dec 1, 1996·Journal of Medical Virology·J CosteM Segondy
Mar 1, 1997·AIDS Research and Human Retroviruses·D J ChoiB J Poiesz
Jan 10, 1998·Clinical and Diagnostic Laboratory Immunology·N L YoungT D Mastro
May 29, 1998·International Journal of Epidemiology·S G WannametheeP Phanuphak
Jun 2, 1998·Vaccine·A LimsuwanD Carlo
Sep 4, 1998·AIDS·V ChurdboonchartD J Carlo
May 24, 2000·The Journal of Infectious Diseases·P H KilmarxT D Mastro
Sep 6, 2000·Clinical and Diagnostic Laboratory Immunology·V ChurdboonchartR Moss
Nov 1, 2000·JAMA : the Journal of the American Medical Association·J O KahnS Lagakos
Oct 24, 2001·HIV Clinical Trials·W SukeepaisarncharoenR B Moss
Nov 28, 2001·JAMA : the Journal of the American Medical Association·R S HoggJ S Montaner
Dec 12, 2001·HIV Medicine·M VelascoA Fernández-Cruz
Dec 12, 2001·HIV Medicine·J L TurnerR B Moss
Apr 19, 2003·Journal of Clinical Microbiology·Daniel R KuritzkesDean L Winslow
Sep 27, 2003·HIV Medicine·A PozniakUNKNOWN BHIVA Writing Committee BHIVA Executive Committee
Aug 11, 2005·Current HIV/AIDS Reports·Kristen Marks, Roy M Gulick
Citations
Aug 11, 2005·Current HIV/AIDS Reports·Yves Lévy
Aug 6, 2005·Autoimmunity Reviews·Aldar S Bourinbaiar, Rivka Abulafia-Lapid
Jul 14, 2009·AIDS Patient Care and STDs·Sharon M ColemanCarol R Tobias
Sep 22, 2007·AIDS·Gregorio A MillettRoger Bakeman
Sep 17, 2004·HIV Medicine·J D Lundgren
Apr 13, 2007·Journal of Immune Based Therapies and Vaccines·Gareth A D HardyFrances M Gotch
Sep 11, 2012·Retrovirology·Guido Vanham, Ellen Van Gulck
Jun 10, 2016·Retrovirology·Barbara EnsoliUNKNOWN SMU-MeCRU study group
Jun 9, 2016·Expert Opinion on Biological Therapy·Gina M Graziani, Jonathan B Angel
Nov 6, 2014·PloS One·Yuan DongJianqing Xu
Apr 29, 2011·Journal of Women's Health·Olga Villar-LoubetStephen Weiss
Nov 23, 2018·Plant Biotechnology Journal·Lianhe ZhangChengcai Chu
Jan 1, 2006·Current Opinion in HIV and AIDS·Sonya L Heath, J Michael Kilby
Jul 20, 2005·Expert Review of Vaccines·Aldar S Bourinbaiar, Rivka Abulafia-Lapid
Mar 15, 2006·Journal of Immunotherapy·Glenn A Van den BoschViggo F I Van Tendeloo